Abbott Laboratories (ABT) Valuation

Based on the GoodMoat Investment Framework's valuation assessment, Abbott Laboratories (ABT) does not present an attractive margin of safety. The primary valuation tool is the Discounted Cash Flow (DCF) model, which yields the GoodMoat Target of $72.81. The current price of $104.83 is significantly above this estimate, representing a -44% margin of safety. According to the framework's MoS bands, any value below 10% is considered 'Unfavourable,' and a negative margin clearly fails this test. The forward P/E of 27.9x must be contextualized against the company's growth rate. With a revenue growth of just 4.4% YoY, this multiple appears high; the framework notes that a P/E of 25-26x can be reasonable for a 50% grower but is high for a slower-growing company. While the P/E might be compared to the sector average, the key principle is that valuation must be justified by the company's own fundamentals, particularly its growth and quality. The stock's quality, indicated by metrics like a solid ROE of 12.4% and a reasonable debt level, is overshadowed by the severe overvaluation relative to the DCF-derived intrinsic value. For a value investor seeking a margin of safety, the current price does not meet the framework's criteria for being 'Favourable' or even 'Marginal.' Analysis based on data as of 2024-05-15.